1. Norway Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Gentian Diagnostics ASA

Gentian Diagnostics ASA

38.80
NOK
+1.80
(+4.86%)
-0.93EPS
527.14MMarket Cap
Feb 18Next Earn
Gentian Diagnostics ASA
STO:GENTO
(Nasdaq Stockholm)

Recent

price

38.80

P/E

ratio

- -

div

yld

2.58%

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
NOK
2.06
2.2
2.3
2.77
2
2.99
3.11
4.15
5.39
6.59
8.76
9.86
11.44
11.92
Revenue per Share
0.08
-0.26
-0.29
-0.8
-1.08
-1.29
-2.59
-1.13
-1.61
-1.53
-0.69
2.94
0.86
-0.93
Basic EPS, GAAP
-0.1
-0.5
-0.79
-1.35
-1.82
-1.08
-1.66
-1.23
-2.59
-1.86
0.71
0.16
2.06
0.25
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.4
1
Dividend per Share
0.15
0.66
8.53
10.37
14.04
15.97
13.52
12.63
11.33
10
9.51
12.58
13.29
11.82
Book Value per Share
-0.28
-0.03
6.78
8
11.89
14.18
12.6
11.61
9.71
8.26
8.14
10.74
10.97
11.53
Tangible Book Value per Share
11
11
11
11
14
15
15
15
15
15
15
15
15
15
Basic Weighted Avg Shares
23
25
26
31
28
46
48
64
83
102
135
152
176
184
Sales/Revenue/Turnover
5.09
-4.66
-6.6
-32.55
-57.98
-33.93
-56.63
-34.71
-27.49
-22.86
-9.44
10.34
14.42
-7.62
Operating Margin (%)
- -
1
1
2
3
4
6
7
7
10
10
9
9
9
Depreciation Expense
1
-3
-3
-9
-15
-20
-40
-17
-25
-24
-11
45
13
-14
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
48.35
- -
Effective Tax Rate (%)
3.82
-11.85
-12.59
-28.89
-54.29
-42.94
-83.12
-27.3
-29.83
-23.24
-7.88
29.78
7.51
-7.82
Profit Margin (%)
3
-1
74
84
160
214
188
172
145
117
116
132
150
154
Working Capital
7
- -
- -
- -
- -
1
2
18
14
12
9
6
19
17
LT Debt
2
7
95
116
196
246
208
195
175
154
147
194
205
183
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.91
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.3
- -
Return on Capital (%)
- -
-64.53
-6.29
-8.48
-9.72
-8.95
-17.55
-8.67
-13.43
-14.36
-7.08
26.59
6.64
-7.44
Return on Common Equity (%)

Capital Structure

NOK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
19
18
17
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
851
601
527

Working Capital

NOK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
184
186
178
Cash, Cash Equivalents & STI
106
92
79
Accounts Receivable, Net
14
39
45
Inventories
54
55
53
Total Current Liabilities
34
33
24
Payables & Accruals
- -
- -
- -
ST Debt
4
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

NOK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.6%
2.22%
5.62%
Free Cash Flow
117.05%
207.21%
1,169.68%
Net Income, GAAP
-29.12%
-122.77%
-70.73%
Sales/Revenue/Turnover
22.74%
22.75%
16.06%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
39
38
33
43
152
2025
45
44
- -
47
176
2026
44
50
- -
- -
- -

Quarterly Earnings Per Share

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.27
0.31
0.22
2.14
2.94
2025
0.5
-0.13
- -
0.22
0.86
2026
-1.32
0.29
- -
- -
- -

Quarterly Dividends Per Share

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
0.4
- -
- -
0.4
2026
- -
0.6
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Gentian Diagnostics ASA develops and manufactures high-quality in vitro diagnostic reagents utilizing particle-enhanced turbidimetric immunoassay (PETIA) technology for use on automated clinical chemistry analyzers; its core products include Cystatin C immunoassay for glomerular filtration rate assessment, GCAL for calprotectin in plasma and serum to detect inflammation and infections, fCAL turbo and fPELA turbo for fecal markers of inflammatory bowel disease and pancreatic exocrine insufficiency, Canine CRP for veterinary C-reactive protein detection, Retinol Binding Protein for vitamin A transport evaluation, and NT-proBNP immunoassay in development for heart failure diagnosis; the company also distributes third-party products from BÜHLMANN Laboratories in the Nordic region via its Swedish subsidiary Gentian Diagnostics AB. Founded in 2001 and headquartered in Moss, Norway, Gentian Diagnostics serves global human and veterinary diagnostics markets through OEM partners, distributors, and representative offices in Sweden, the United States, and China, targeting laboratories and healthcare providers in areas such as kidney disease, cardiac conditions, inflammation, infection, and veterinary medicine. Recent developments include the launch of GCAL into market development phase, strong revenue growth with 19% organic increase to NOK 129.9 million in the first nine months of 2025, acquisition of Getica AB in 2023 for SEK 3.0 million to enhance antibody purification and R&D capabilities with operational synergies from 2024, expansion plans for Gentian Diagnostics AB into Finland and Denmark, and ongoing feasibility work on a novel detection platform to improve sensitivity beyond conventional PETIA systems.